SABCS 2021 Updates in ER+ Breast Cancer

EP: 1.Coming Soon: THE TALK: Breast Cancer, A Review of Data from the SABCS 2021 Virtual Meeting

Now Viewing

EP: 2.SABCS 2021 Updates in ER+ Breast Cancer

EP: 3.SABCS 2021 Updates in CDK4/6 Inhibitors in Breast Cancer

EP: 4.SABCS 2021 Updates in Key Clinical Trials for Breast Cancer

Data from the following clinical trials are discussed:

• P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor degrader (SERD), combined with palbociclib [Ibrance] in postmenopausal women with ER+/HER2 advanced breast cancer
• GS2 -02: Elacestrant, an oral selective estrogen receptor degrader (SERD) vs investigator's choice of endocrine monotherapy for ER+/HER2 advanced/metastatic breast cancer following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial
• PD13-08: First-in-human safety and activity of ARV-471, a novel PROTAC estrogen receptor degrader, in ER+/HER2 locally advanced or metastatic breast cancer